Primary Immune Thrombocytopenic Purpura
Conditions
Keywords
ITP
Brief summary
To select a dose and to make a decision for Phase 3 study
Detailed description
The onset of primary immune thrombocytopenia is thought to be increased platelet destruction and decreased platelet production due to anti-platelet antibodies. HBM9161 is a fully human anti-FcRn monoclonal antibody that can effectively remove pathogenic IgG, thereby relieving platelet destruction and rapidly increasing platelet counts in patients. The study will be conducted in a Phase 2/3 operational seamless design, with group Dose A and Dose B of HBM9161 and a placebo group in Phase 2.
Interventions
DRUGHBM9161 Dose A
HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
DRUGHBM9161 Dose B
HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
DRUGPlacebo
HBM9161 (Dose A or Dose B) or matching placebo will be administered IV weekly
Sponsors
Harbour BioMed (Guangzhou) Co. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥ 18 years of age at the screening visit, male or female. 2. Persistent or chronic ITP whose average number of platelet at the screening visit and pre-dose (at least 1 day apart) is \< 30 × 10\^9/L, and not \> 35 × 10\^9/L for any of two tests. No severe bleeding within 4 weeks prior to the screening visit. 3. Patients who have received and failed at least 1 first line of ITP therapy (glucocorticoids and/or intravenous gamma globulin), or who are contraindicated, intolerable, or refuse standard therapy. 4. Patients will be allowed to use a stable dose of concomitant drugs for the treatment of ITP. e.g., glucocorticoid, danazol, immunosuppressant (azathioprine, cyclosporine A, mycophenolate mofetil) and eltrombopag.
Exclusion criteria
1. Other autoimmune systemic diseases other than ITP. 2. Multi-lineage immune cytopenias, such as Evan's syndrome, autoimmune pancytopenia. 3. Secondary ITP. 4. Received a vaccine within 4 weeks prior to the first dose of the study drug or planned during the study. 5. Use of anticoagulants or any agents that have antiplatelet effect or can affect thrombopoiesis within 3 weeks prior to the first dose of the study drug. 6. Received blood transfusion within 1 week prior to the first dose of the study drug. 7. Received the intravenous gamma globulin, anti-D immunoglobulin, or plasmapheresis within 2 weeks prior to the first dose of the study drug. 8. Received high-dose dexamethasone or high-dose methylprednisolone within 2 weeks prior to the first dose of the study drug. 9. Received recombinant human thrombopoietin (rhTPO) within 4 weeks prior to the first does of the study drug. 10. Received rituximab or other non-rituximab anti-CD20 drugs within 6 months prior to the first does of the study drug. 11. Treated with splenectomy within 4 weeks prior to first dose of the study drug. 12. Any thromboembolic or embolic events within 12 months prior to the first does of the study drug. 13. Serum total IgG \< 700 mg/dL at the screening visit.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who achieve the early response. | 7 weeks | The primary endpoint of phase 2 |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients who achieve platelet count ≥ 50 × 10^9/L at least 2 times within 7 weeks. | 7 weeks |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORRenchi Yang
Hematology hospital, Chinese academy of medical sciences
Outcome results
None listed